Here are seven things to know:
1. Orthofix International received an average broke rating score of 1.00 from the two brokers providing coverage of the stock, thus indicating a “strong buy“ rating.
2. Analysts set a 12-month consensus target of $39.00 for the company and are anticipating the company will post $0.05 EPS.
3. Analysts at Zacks provided Orthofix International NV an industry ranking of 106 out of 265 based on the ratings given to similar companies.
4. Orthofix stock has a 50-day moving average of $33 and a 200-day moving average of $32.
5. The company has a market cap of $653.81 million.
6. Orthofix International NV reported a quarterly revenue of $89.50 million, indicating a 10.2 percent decrease on a year-over-year basis.
7. Numerous analysts have commented on OFIX shares with Zacks’ analysts upgrading Orthofix from a “sell” rating to a “hold” rating in a research note released Wednesday, June 10.
For more device related news:
7 notes on the orthobiological products market
Implanet enrolls 1st patient in Jazz Band spine trial — 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
